← Browse by Condition
Medical Condition

brachytherapy

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for brachytherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — brachytherapy Clinical Trials

How many clinical trials are currently recruiting for brachytherapy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for brachytherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for brachytherapy?
brachytherapy research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a brachytherapy clinical trial?
Eligibility criteria for brachytherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
Fujun Zhang 1 trial
University of Utah 1 trial
Clinica Universidad de Navarra, Universidad de Navarra 1 trial

Recruiting Clinical Trials

NCT05894018 Phase 2
Recruiting
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
Enrollment
32 pts
Location
China
Sponsor
Fujun Zhang
View Trial →
NCT05979610 Phase 2
Recruiting
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
Enrollment
70 pts
Location
United States
Sponsor
University of Utah
View Trial →
NCT06982469
Recruiting
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
Enrollment
20 pts
Location
Spain
Sponsor
Clinica Universidad de Navarra...
View Trial →

Related Conditions

sarcoma soft tissue (1) poly adp ribose polymerase inhibitors (1) gynecologic neoplasm (1) therapeutic touch (1) endometrial cancer (1) cervical cancer (1) vaginal cancer (1) vulvar cancer (1) prostate cancer (1) prostatectomy (1) local recurrence of malignant tumor of prostate (1) radiotherapy complications (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology